T1	Limited_variation	14 21	KRAS MT
T2	Phenotype	55 71	progression-free
T3	Phenotype	76 92	overall survival
T4	Disease	105 119	NSCLC patients
T5	Chemical	153 183	platinum -based chemotherapy .
R1	decreases	Arg1:T1	Arg2:T2
R2	decreases	Arg1:T1	Arg2:T3
R3	treats	Arg1:T1	Arg2:T4
R4	isAssociatedWith	Arg1:T2	Arg2:T1
R5	decreases	Arg1:T2	Arg2:T3
R6	isAssociatedWith	Arg1:T2	Arg2:T4
R7	isAssociatedWith	Arg1:T3	Arg2:T1
R8	decreases	Arg1:T3	Arg2:T2
R9	isAssociatedWith	Arg1:T3	Arg2:T4
R10	isAssociatedWith	Arg1:T4	Arg2:T1
R11	decreases	Arg1:T4	Arg2:T2
R12	decreases	Arg1:T4	Arg2:T3
R13	decreases	Arg1:T5	Arg2:T2
R14	decreases	Arg1:T5	Arg2:T3
R15	treats	Arg1:T5	Arg2:T4
